

January 10, 1969

Dr. B. Blackwell, M.D.
Wm. S. Merrill Co.
Cincinnati, Ohio

Dear Dr. Blackwell,

I have read both the information brochure and the proposed protocol for studies of Dimethacrin in depressive disorders. While such problems are of interest to this laboratory, we have recently decided that our energies were better spent in the analysis of EEG profiles of new compounds, to determine the logical populations of risk and the classification of the compound.

Such profile analyses have been of special interest to industry in the study of new chemical structures, and we would be pleased to review the animal pharmacology of compounds that are of interest to you. The classification of this compound seems to have been decided by the Swiss workers and the research staff of Merrill Co. has apparently accepted this determination. If this interpretation is incorrect, and there is interest in reviewing the population of risk for Dimethacrin, I would be pleased to review the data with you.

Good luck in your new appointment, and I look forward to meeting you at the next ECDEU meeting, or earlier, if the opportunity presents itself.

Sincerely yours,

Max Fink, M.D.

mf/